So far it has therefore been believed that the relative frequency of the different HRAS mutations in cancer and CS simply reflects differences in the oncogenic potential of the encoded proteins and differences in the rate they occur by spontaneous mutations. This evidence concerns the gene HRAS and Cowden syndrome 1.